FDA approved First-in-Class Androgen Inhibitor Acne Cream
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Cassiopea SpA on 27 August announced that the United States Food and Drug Administration (FDA) approved Winlevi® (clascoterone cream 1%) for the treatment of acne in patients 12 years and older.

• Cassiopea’s first-in-class topical androgen receptor inhibitor, WINLEVI, tackles the androgen hormone component of acne in both males and females.

• Androgen receptor inhibitors act by limiting the effects of these hormones on increasing sebum production and inflammation.

• In pivotal clinical trials, WINLEVI demonstrated treatment success and reductions in acne lesions and was well tolerated when used twice a day. The most frequently observed local skin reaction was mild erythema.

• Indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

• Most common adverse reactions: Erythema/reddening, pruritus, scaling/dryness, edema, stinging, and burning.

Source: https://www.cassiopea.com/2020/08/27/cassiopea-receives-fda-approval-for-winlevi-clascoterone-cream-1-first-in-class-topical-acne-treatment-targeting-the-androgen-receptor/
Dr. T●●●●z H●●●●●●i and 2 other likes this1 share
Like
Comment
Share